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1. Introduction 
Autism is a developmental disorder defined as a severe and persistent restriction in 
communicative skills, including lack of social and emotional reciprocity, as well as 
stereotyped and repetitive behaviours. Such an impairment of social interaction was already 
described in 1919 by the Swiss psychiatrist Eugen Bleuler within the framework of the 
negative symptom complex of schizophrenia. In the following decades in particularly the 
German language areas of Switzerland, autism was viewed by Kretschmer (1921) as a 
schizoid temperament whereas later, he viewed it as a special form of schizophrenia. In the 
late fifties, Leonhard (1957) assigned this specific disturbance in communication to the so 
called systematic schizophrenias. In 1943, the immigrated American child psychiatrist from 
Austria, Leo Kanner, originally described early infantile autism as Autistic Disturbance of 
Affective Contact. In a study of 11 children, four behavioural characteristics were 
distinguished: severe social withdrawal behavior, obsessive desire for repetitiveness, 
persistent fascination with specific objects or thoughts, and severe language impairments. 
One year later, the Austrian pediatrician Hans Asperger reported comparable findings 
under the title ‘Die ‘Autistischen Psychopathen’ in Kindesalter’. Both Kanner (1943, 1971) 
and Asperger (1944) considered autism a communication disorder for children with severely 
impoverished relations with the environment (i.e., ‘autistic aloneness’).  
Up until the beginning of the 1960s, under the influence of the then prevalent 
psychodynamic theories, autism was largely attributed to family and environmental factors. 
Rutter (1968) placed autism in a different perspective and demarcated the phenotypical 
presentation of both early infantile autism and schizophrenia from their biological 
underpinnings. Lorna Wing (1981) can be credited for bringing the descriptions of Asperger 
from 1944 back to our attention in the 1980s and, on the basis of extensive childhood 
epidemiological research, for placing autism in a broader diagnostic context and developing 
diagnostic criteria (Wing & Gould, 1979). Wing introduced the term ‘autism spectrum 
disorder’, which can be described on the basis of information from three domains: (a) social 
reciprocity, (b) verbal and non-verbal communication and imagination, and (c) a restricted, 
stereotyped pattern of interests and activities. These elements still constitute the diagnostic 
criteria from e.g. the DSM-IV category of Pervasive Developmental Disorders that include 
Autistic Disorder, Rett’s Disorder, Childhood Disintegrative Disorder, Asperger’s Disorder, 
and Pervasive Developmental Disorder Not Otherwise Specified (overview: Kumbier et al. 
2010). 
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In her retrospective ‘Reflections on opening Pandora’s box’ presented a few years back, 
Lorna Wing (2005) warns about stretching the boundaries of the autistic spectrum, which 
presently includes those who have normal to extremely high intelligence at the one end and 
those with a severe intellectual disability and limited social and communicative skills at the 
other end. In such a manner, the diagnostic label of ‘autistic spectrum disorder’ can possibly 
be misused to attain care (Volkmar et al., 2009). This is certainly not  inconceivable in light of 
the quadrupled prevalence of pervasive developmental disorders across a period of 40 years 
(4.1 per 10,000 to 16.8 per 10,000), including somatic/neurological disorders that accompany 
autism (Fombonne, 2003; Rice, 2009). Moreover, autism and Asperger’s disorder are 
regularly associated with other syndromes (Gillberg & Gillburg, 1989; Gillberg and Billstedt, 
2000). As elegantly stated by Gillberg already in 1991 in his Emanuel Miller Memorial 
Lecture, researchers and clinicians, rather than allow themselves to be guided by stereotypic 
(sub)classifications, should be guided by a more balanced view of autism as belonging to a 
group of empathy disorders and thereby start the search for autism-relevant 
endophenotypes (Gillberg, 1992). 
In the following sections, a brief overview of the current neuropsychological and genetic 
explanatory models will first be given. Thereafter, a selection of syndromes with a known 
genetic etiology that are seen to accompany autism will be discussed. To conclude, the 
manner in which modern genetics can be utilized in daily diagnostic practice will be 
elucidated. 
2. Neuropsychological models 
Roughly three explanatory models can be discerned for the pattern of disorders encountered 
in cases of autism. The first model is based upon the weak central coherence (WCC) 
hypothesis, which claims that patients with autism are inclined to attend to details as 
opposed to the whole during the processing of context-based information (i.e., strictly 
feature-based perception). As a consequence, the information is not understand as a 
meaningful whole and thus remains fragmented and confusing (Happé & Frith, 2006; Frith, 
1989). 
The second model draws upon the concept of Theory of Mind, which refers to the capacity to 
attribute thoughts, desires, and intentions to others. This capacity starts to develop around 
the age of three to four years and allows humans to take the perspectives of others into 
consideration in their own thinking. Deficiencies in this domain can easily lead to social 
misinterpretations and socially inadequate behavior, which form the basis of the severe 
communication problems that people with autism show (Baron-Cohen, 1989). In this 
connection, the more general notion of social cognition may be called upon and a link made 
to, for example, diminished activity of the amygdala and deviant perceptions of one’s own 
emotions (Kethrapal, 2008). 
In the last model, that of the dysexecutive functioning hypothesis, disturbed executive 
functions are assumed to play an important role. The executive functions (EF) are of major 
importance for the integration, steering, and control of processes required to execute 
purposeful behavior in new or complex situations. At a structural level, four frontal-
subcortical circuits are involved in EF. The dorsolateral-prefrontal circuit has been related to 
executive cognitive dysfunctioning; the ventromedial circuit has been related to activation 
and motivation problems; and the medial- and lateral-orbitofrontal circuits have been 
related to disturbed affect regulation and disturbed social behavior, respectively (Chow & 
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Cummings, 2007; Alvarez & Emory, 2006). EF often involves the overruling of automatic 
responses in favour of more intentional behaviour. A capacity to flexibly switch between 
different behavioral repertoires (i.e., monitoring and shifting) is required for such overruling 
and typically found to be a problem in cases of autism. Barnes-Holmes and colleagues view 
EF as rule-governed behaviour and thus behaviour that stands in contrast to contingency-
shaped behaviour, which has been automatized. EF thus defined, is verbal behaviour that 
precedes other behaviour (i.e., verbal antecedent behavior) and therefore distracts the 
individual from his usual, automatic reaction pattern. Stated differently, the probability of 
an alternative behavior is changed in the direction of a particular objective. In such a 
manner, thus, recent research on rule-governed behaviour connects EF with autism and an 
underlying Theory of Mind (Barnes-Holmes et al., 2004; McHugh et al, 2004). 
3. Genetic models 
Autism can be viewed as a classic example of a disorder with a strong genetic basis. A 
distinction must nevertheless be made between the Autistic disorder as originally described 
by Kanner and the autism spectrum disorder, which can be viewed as a component of an 
array of clinical pictures and syndromes that are sometimes referred to as secondary or 
syndromic autism (Benvenuto et al., 2009). Given the complex interplay between genes and 
autism, a search for at least two types of genetic factors is of importance, namely: (rare) 
chromosomal  abnormalities or gene alterations that can be directly related to core (i.e., 
classic) autism and  genetic copy number variants that correlate with a vulnerability to 
develop an autistic disorder. 
In several studies from the 1980s and 1990s that use a strict definition of autism, a 69% to 
95% concordance has been demonstrated in monozygotic twins, while the chance in 
dizygotic twins is only 0% to 24%. The contribution of the hereditary components is 
estimated to be 90%. The male-female ratio is between 3-4 to 1 (Brkanac et al., 2008). In order 
to advance the understanding of the genetic heterogeneity of autistic disorders, various 
techniques can be used such as (molecular) cytogenetic research, linkage studies, and 
association studies.  
Linkage studies search for those parts of a chromosome that are found to be the same for all 
affected individuals in a family but different for the non-affected family members. A gene 
that contributes to the occurrence of a vulnerability for autism may lie in such a shared 
region. These studies have revealed a wide variety of loci, from which a considerable genetic 
heterogeneity can be concluded as well as the absence of single, specific locations for autism 
(Szatmari et al., 2007). Recently, in a very large-scale linkage study, two new locations have 
been found on chromosomes 6 and 20 (6q27 and 20p13, respectively) for which the 
functional significance has yet to be clarified (Weiss et al., 2009). 
The same holds for candidate genes that have been implicated in a large series of association 
studies. These studies investigate significant genetic differences between large groups of 
patients, on the one hand, and groups of healthy individuals, on the other hand (Vorstman 
et al., 2006a). The research findings make it clear, however, that the pathophysiology of 
autism involves genes that code for proteins from the family of neurexins and neuroligins 
that play, in turn, a role in the development and functioning of synaptic and in particular 
glutamatergic and GABA-ergic networks (Lisé & El-Husseini, 2006; Buchsbaum, 2009). The 
first X-linked mutations in genes involved in the coding of neuroligin were revealed in 
patients with autism in two Swedish families in 2003 (Jamin et al., 2003). 
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When the classic microscopic cytogenetic route is followed, structural chromosomal 
aberrations are found in 3% to 7% of patients with autism and developmental delay. This 
finding concerns mainly maternal duplications on the long arm of chromosome 15 (q11-13) 
(Hogart et al., 2010) and deletions on the long arm of chromosome 2 (q37) (Falk & Casas, 
2007), chromosome 7 (q22 and q31) (Alarcón et al., 2002) and chromosome 22 (q11) 
(Niklasson at al., 2009) and (q13) (overview: Kumar & Christian, 2009). The fluorescence-in-
situ-hybridization (FISH) technique is used to search for specific submicroscopic deletions 
and is used primarily to confirm a clinical diagnosis such as the 22q11 deletion syndrome. 
Disadvantages of this technique are its labor intensiveness and that only one or a few 
chromosome regions can be examined per experiment. 
More commonly used these days is the whole-genome microarray technique. Here, details 
more than a hundred times smaller can be perceived when compared to microscopic 
cytogenetic examination (de Vries et al., 2005; Veltman & de Vries, 2006). With the aid of 
such a ‘DNA chip’, the complete genome with a high resolution can be examined for the 
presence of microdeletions and duplications or so-called copy-number variations (CNVs). 
Of principal concern here are small quantitative, structural variations that are paired with a 
loss or gain of chromosome material. Furthermore, the ‘targeted genomic array’ technique 
can be applied to study specific regions such as the subtelomeric chromosome regions or 
well-known microdeletion syndrome regions (Lintas & Persico, 2009). 
For various neuropsychiatric disorders including autism, CNVs possibly involved in the 
vulnerability for the development of a disorder within the autism spectrum have been 
demonstrated using the array technique (Jacquemont et al., 2006; Cook & Scherer, 2008). For 
some of these CNVs, a clear correlation has been demonstrated, e.g., a maternal 15q11-q13 
duplication was shown for 1-3% of patients with an autistic spectrum disorder. Another 
frequently occurring CNV is found on the chromosome 16p11.2 which present with a 
deletion or duplication in approximately 1% of the patients (Weiss et al., 2008; Fernandez et 
al., 2010).  
There are, however, also CNVs found with an, as yet, unknown significance; because, for 
example, the same change can be traced back to a healthy parent. A precise interpretation of 
the array results with the aid of bio-informatics, literature databases, data from the pedigree 
and clinical investigation of affected individuals, is therefore essential. 
Another interesting perspective is the neuropeptide concept. It has been known for quite 
some time that the nonapeptide oxytocine (OXT) is involved in affiliation behaviour and 
social cognition via an improvement of social memory, including the recall and 
understanding of affective events (Hollander et al., 2007; Insel, 2010; Green & Hollander, 
2010). For these reasons, research has been performed on the association between single 
nucleotide polymorphisms (SNPs) in the OXT gene and the OXT receptor gene (OXTr). 
Relative to the normal population, more SNPs were present in the OXTr for a subgroup of 
patients with autism, which could indicate a genetically determined vulnerability for the 
development of autism (Lerer et al., 2008; Lee et al., 2009). In line with these observations, 
Gregory et al. (2009) found that epigenetic regulation of OXTr is implicated in the 
development of autism. 
To summarize, in linkage and association studies among patients with autistic disorders up 
until now, a large number of candidate genes and gene locations have been found for which 
it can be assumed that they may be involved in the development of functional processes of 
the central nervous system. In Table 1, a selective overview is presented.  In the following 
section, the most well-known genetic disorders associated with autism will be discussed. 
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Chromosome Candidate Gene Network/Function 
2p16.3 NRXN1 Synapse formation 
2q12.3-q14.2 DPP10 Neurotransmission 
3p24-26 OXTr Neurotransmission 
3p26-p25 CNTN4 Synapse formation 
4p14-q21.1 GABRG/GABRA GABA neurotransmission 
7q31.1 ST7 Tumor suppression 
7q35-q36 CNTNAP2 Synapse formation 
8p23 DLGAP2 NMDA neurotransmission 
15q11-q14 GABRA/GABRB/GABRG GABA neurotransmission 
15q13 APBA2 Neurotransmission 
16p11.2 DOC2A Neurotransmission 
22q11 PRODH Neuromodulation 
22q13 SHANK3 Synapse formation 
Xp22.3 NLGN4 Synapse formation 
Xp11.4 TSPAN7 Neuronal growth and development 
Xp22.1-p21.3 IL1RAPL1 Interleukin receptor 
Table 1. Selection of genes and functions possibly involved in autism (adapted from 
Guilmatre et al., 2009 and El-Fishawy & State, 2010) 
4. Genetic syndromes and autism 
4.1 Fragile X syndrome 
The fragile X syndrome (FXS; Figure 1) is the most well-known genetic disorder related to 
autism. Brown and colleagues (1982) were the first to report on this. Initially, FXS was 
described by Lubs (1969), who detected a fragile site at the end of the long arm of the X 
chromosome by using classical microscopic cytogenetic techniques. FXS is caused by 
hypermethylation of an expanded trinucleotide repeat (CGG) in the ‘fragile X mental 
retardation 1 (FMR1) gene’ (Xq27.3). In normal individuals, the number of CGG repeats is 5 
to 45 which is stably transmitted to the next generation. In case of a FMR1 premutation, 
there is a small expansion of 55 to 200 repeats. In FXS, the number of repeats exceeds 200. As 
a result of this enlarged number of repeats, hypermethylation of the FMR1 gene occurs 
which leads, in turn, to a shortage or complete loss of the FMR1 protein that is essential for 
dendrite formation, synapse formation, and experiential learning (Marco & Skuse, 2006; 
Hernandez et al., 2009). 
FXS is an X-linked disorder with an incidence of about 1 in 4000 newborn males. Affected 
males show a variable degree of developmental delay, behaviour problems, and distinctive 
dysmorphic features such as a long face and large, prominent ears. Female carriers with a 
full mutation (>200 repeats) may present with or without impaired level of intelligence. 
Females with FXS and normal intelligence, however, have an increased risk of mood and 
anxiety disorders and a schizotypical personality disorder (Franke et al., 1998).  
In males with a premutation (50-200 repeats), there is an increased probability of the 
development of the so-called fragile-X-associated tremor/ataxia syndrome (FXTAS). Its 
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symptoms emerge at a later age, and the syndrome has a progressive course. The clinical 
picture comprises intention tremor, frequent falling, Parkinsonian symptoms, and disturbed 
cognitive and executive functioning (Verhoeven et al., 2008; Bourgeois et al., 2009).  
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Fig. 1. Fragile X syndrome and the FMR1 gene 
Schematic representation of the location of the FMR1 gene on the long arm of the X chromosome. (a) 
The FMR1 gene comprises a polymorph repetition of the base pairs cytosine-guanine-guanine (CGG) 
at the start of the gene. In healthy individuals, this number of CGG repeats varies from 5 to about 45 
units. (b) Affected individuals have more than 200 CGG repeats: the full mutation. (c) The expansion 
to a full mutation (>200 repeats is usually associated with hypermethylation of the CGG repetition 
and the adjacent area, which leads to a  transcription stop resulting in the absence of the FMR1 
protein. This results in intellectual disability and other symptoms of the Fragile X syndrome among 
men, and in >50% of the women who are carriers of a full mutation. Carriers with 55 and 200 repeats 
are asymptomatic and are thus called premutation carriers 
For decades, it has been known that the severity of intellectual disability and the intensity of 
related behaviour problems is proportional to the number of repeats. The 
psychopathological phenotype of FXS includes, in addition to the developmental delay, 
multiform anxiety symptoms, obsessive-compulsive characteristics, hyperactivity / 
impulsivity, and aggression. Epileptic phenomena are frequent. Predominant, however, are 
autism-related symptoms such as social anxiety and withdrawal behaviour, stereotypies like 
flapping or biting of the hands, perseverations, extreme sensitivity to environmental stimuli, 
and, in general, decreased social reciprocity with an avoidance of eye contact (Hagerman, 
2005).  
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Using neuroimaging techniques, various structural abnormalities of the central nervous 
system can be demonstrated, in particular enlargement of hippocampus, amygdala, 
caudatus, and thalamus with a reduction of the cerebellar vermis (Hessl et al., 2004). These 
neuronal changes are caused by an overabundance of immature dendritic spines. In normal 
conditions, dendritic spines are essential for the formation of new neuronal connections that, 
in turn, form the basis for learning and memory. In FXS, the cognitive dysfunctions in the 
domains of attention, (working) memory, mathematical skills, executive functioning and 
social cognition largely correspond to the observed abnormalities of the central nervous 
system.  
The treatment of patients with FXS is primarily symptomatic and aimed at the reduction of 
the most prominent behavioural problems or psychiatric symptoms, such as anxiety, 
hyperactivity, impulsivity and distractibility (Garber et al., 2008). Since the extremely 
heightened sensitivity to environmental stimuli is assumed to underlie the above mentioned 
symptoms, it is essential to reduce excessive environmental sensory activation. This can be 
achieved with a more structured daily program of activities, the promotion of a realistic 
pattern of expectations among parents/caregivers, individualized instruction and, most 
importantly, the dissemination of knowledge about the persistence of the FXS behavioral 
phenotype. 
4.2 Rett syndrome 
Rett syndrome (RS) was first described in 1966 by Andreas Rett. This syndrome is inherited 
in an  X-linked manner, caused by a mutation in the Methyl-CpG-Binding Protein 2 
(MECP2) gene (Xq28). In Figure 2, the location of the MECP2 gene is depicted. RS occurs 
almost exclusively in girls and its prevalence is estimated to be between 1/10,000 - 1/20,000. 
In boys, the disorder is nearly always lethal. In rare male cases, an extra X chromosome or 
mosaicism of the MECP2 mutation has been found.  
RS is characterized by an apparently normal development in the first 6 to 18 months of life 
after which development stagnates, acquired skills get lost and development finally stops. 
This stagnation of development also becomes manifest in a retarded and disproportionate 
growth in head circumference, decrease of eye contact, and both cognitive and motor 
deterioration. Already in the first year of life, autistic behavioural elements are present such 
as social withdrawal, declining speech and communication, limited eye contact, grinding of 
the teeth, and characteristic hand stereotypies (Ben Zeev, 2007; Gonzales & LaSalle, 2010). In 
the majority of the patients, the syndrome is associated with severe epilepsy. The first 
decade is dominated by severe neurological dysfunctions and an irregular respiration 
pattern as a result of an immaturely developed brainstem. In addition, a prolonged QT 
interval is often present with, as a consequence, risk for sudden cardiac arrhythmia. From 
the age of 10, a developmental plateau occurs and the patient becomes severely 
neurologically handicapped with profound intellectual disability. 
In 80% to 90% of the patients with RS, a mutation that almost always occurs de novo, can be 
demonstrated in the MECP2 gene. This gene is expressed particularly in neurons and to a 
lesser extent in glial cells, and involved in neuronal maturation in the postnatal period. 
MECP2 is involved in the expression of the gene that codes for brain derived neurotrophic 
factor (BDNF), which is essential for neuronal maturation and plasticity. The 
pathophysiology of RS thus lies conceivably in a MECP2–mediated disturbance in the 
regulation of BDNF. It is assumed that the severity of the disorder and the progression over 
time of the successive stages corresponds with a polymorphism in BDNF (Matijevic et al., 
2009; Ben Zeev et al., 2009). 
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RS is one of the better examples of an autism-related disorder with a proven genetic 
pathophysiology. While there are clear differences between classical autism and the 
phenotypic presentation of autism in RS (i.e., characteristic stereotypy such as hand-
wringing at chest level and a relative maintenance of eye contact), research in RS could 
nevertheless contribute to a better understanding of involvement of central nervous system 
dysfunctions in autism.  
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Fig. 2. Rett syndrome and the MECP2 Gene 
Schematic representation of the location of the MECP2 gene on the long arm of the X chromosome. 
(a) The MECP2 gene is constituted by 4 coding exons.The majority of mutations among patients with 
Rett syndrome are found in exon 4. In addition, in more than 10% of the patients, a deletion of the 
last part of exon 4 is present. The terms 5’ UTR (UnTranslated Region) and 3’ UTR indicate the 
direction in which the gene is read; from 5’ UTR to 3’ UTR 
4.3 Tuberous sclerosis 
Tuberous sclerosis complex (TSC) of Bourneville-Pringle was first described in 1880 by 
Bourneville and is a multi-organ disorder with a autosomal dominant inheritance. The 
prevalence is 1 in the 6,000 - 10,000 births. TSC is caused by mutations in two genes, the TSC 
1 and 2 gene. The TSC1 gene is located on chromosome 9 (9q34.3) and codes for hamartin 
while the TSC2 gene is located on chromosome 16 (16p13.3) and codes for tuberin. In 
approximately 85% of patients with a clinically confirmed diagnosis of TSC, a change in one 
of these two genes can be demonstrated. Usually, a de novo mutation is present, although 
30% of the index patients has one or more affected family members. Mutations in both genes 
can lead to abnormal cell growth and differentiation in multiple organ systems. In the brain, 
this is expressed by the formation of cortical and subcortical hamartomas including tubers. 
In addition, various organ systems can be affected leading to the development of cystic 
kidneys, angiofibromas of the face, and rhabdomyomas. The structural abnormalities of the 
www.intechopen.com
 
Autism and Genetic Syndromes 
 
39 
central nervous system are associated with various forms of epilepsy, cognitive 
dysfunctions and symptoms of autism (Datta et al., 2008). There is, however, a great 
variability in the severity of the clinical characteristics across TSC patients, also within one 
single family. 
Already in 1932 and thus before Kanner’s publication, Critshley and Earl described the autistic 
characteristics associated with TSC, being decreased social contact, stereotypies, disturbed 
speech, and withdrawal behaviour. Research during the last few decades has shown autism to 
occur in about 25 to 60 percent of TSC patients, although its symptom profile differs 
qualitatively from that seen in classical autism. A higher level of social-cognitive functioning 
as well as less pronounced stereotypies are characteristic of patients with TSC. Moreover, in 
contrast to autism, the male-female ratio in TCS is about equal (Wiznitzer, 2004). 
The neurobiological substrate for autism in TSC is still unclear. For both hamartin and 
tuberin, it is assumed that both proteins modulate cell function and play a role in neuronal 
migration, differentiation, and development and that they together form a functional 
complex (Asato et al., 2004). The latter can be considered as a type of ’neuronal polarity’ in 
which over expression of the TSC1/TSC2 complex suppresses the formation of axons while 
an under expression is associated with the formation of tubers (Choi et al., 2008). This 
TSC1/TSC2 functional integration may explain that a mutation in one of the two genes can 
result in the same phenotype (Orlova & Crino, 2010). Finally, it has been demonstrated that 
the number of tubers in the brain correlates with the incidence of autism and that their 
localization corresponds with the type of epilepsy (Marcotte & Crino, 2006). 
In sum, also for TSC, it is clear that the presence of autistic behavioural characteristics 
relates to a well-defined gene defect. This knowledge from TSC research may further 
elucidate the pathophysiology of autism. 
4.4 22q11 deletion syndrome  
The 22q11 deletion syndrome (22q11DS) was first described in 1978 by Shprintzen as velo-
cardio-facial syndrome and is caused by an interstitial deletion of chromosome 22 (22q11.2). In 
Figure 3, a micro-array profile of chromosome 22 from a patient with 22q11DS is depicted. 
This syndrome is associated with, among others, congenital heart and conotruncal defects, 
cleft palate, hypoparathyroidism, and facial dysmorphisms. The prevalence of 22q11DS is 
1:4,000 with an equal male-female distribution. The deletion involved in this syndrome can 
encompass multiple genes, with the T-box 1 (TBX1) gene as the most important. Its encoded 
protein is crucial for the development of specific brain areas, heart, face, and limbs (Paylor et 
al., 2006). It is, however, doubtful whether this gene also plays a role in the etiology of 
psychiatric disorders that often accompany 22q11DS (Funke et al., 2007). 
During the past decades, it has become clear that psychiatric disorders often occur in 
22q11DS patients. These include psychoses in particular (Vogels et al., 2002; van Amelsvoort 
et al., 2004; Verhoeven et al., 2007), but also anxiety, mood, and obsessive-compulsive 
disorders (Shprintzen, 2000). In addition, in 15% to 30% of the patients with 22q11DS, 
autistic features are present such as withdrawal behaviour, impaired social interaction, 
reduced facial expression, and cognitive deficits, e.g., perseveration, reduced mental 
flexibility, and restricted problem-solving capacities (Fine et al., 2005; Vorstman et al., 2006b; 
Anshel et al., 2007; Niclasson et al., 2009). Closer inspection of the psychopathological 
profile has demonstrated that both the psychotic and the autistic symptoms evolve from a 
diminished comprehension of abstract and symbolic language, in addition to a limited 
capacity to correctly estimate the intentions, emotions, and behaviour of others (Sphrintzen, 
2000; Verhoeven et al., 2007).  
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In sum, for 22q11DS, it is obvious that detailed analysis of the cognitive, emotional, and 
psychiatric profile is of critical importance for the choice of an individual treatment strategy.  
 
Fig. 3. Microarray profile of chromosome 22 from a patient with 22q11DS  
(a) Representation of a microarray profile of chromosome 22 from a patient with a 22q11 deletion. (b) 
The ideogram  of chromosome 22 with the indication of short p arm and the long q arm is depicted 
underneath.. In the upper portion, every individual clone is represented separately by a red dot on the 
X axis running between the end of the p arm (left) and the end of the q arm (right). On the Y axis, the 
amount of DNA from the patient as compared to that from control samples (CK) can be read. In case 
of an equal amount, the log2 ratio approximates zero. In cases of deletion, this  will be -1 or lower. In 
cases of duplication, this will be +1 or higher. The p arm of chromosome 22 is not represented in the 
microarray profile because it only consists of satellites and non-coding material 
4.5 Metabolic disorders  
While genetically determined metabolic disorders are relatively rare, nevertheless, they 
often manifest with disorders along the autistic spectrum. The establishment of such a 
diagnosis is of importance for not only treatment and prognosis but also for gaining more 
insight into the pathophysiology of autism. Primarily involved are disturbances in amino 
acid metabolism such as phenylketonuria, disorders in purine metabolism, creatine 
deficiency syndromes, Smith-Lemli-Opitz syndrome (i.e., an inherited defect in the 
synthesis of cholesterol), urea cycle disorders, and mitochondrial disorders (Manzi et al., 
2008; Zecavati & Spence, 2009; see Table 2). The latter may even have its debut with 
symptoms from an autism spectrum disorder (Weissman et al., 2008). 
From the metabolic disorders, the creatine deficiency syndromes represent a recently 
recognized group of diseases that are caused by inherited defects in the biosynthesis and 
transport of creatine. Two defects in the biosynthesis have been reported that include 
deficiencies of the enzymes L-arginine-glycine amindinotransferase (AGAT) and 
guanidinoacetate methyltransferase (GAMT). The third is a functional defect involving the 
creatine transporter mechanism. The latter is an X-linked syndrome caused by a defective 
creatine transporter and was first described by Salomons et al. (2001). It appeared to be the 
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result of a mutation in the creatine transporter gene called SLC6A8 that was mapped to 
Xq28. Its prevalence is estimated to be at least 2% of X-linked mental retardation syndromes 
(Rosenberg et al., 2004). Since the SLC6A8 gene is expressed in most tissues (e.g. skeletal 
muscle, kidney, colon, brain and heart), several organ systems can be affected. 
 
Disorder First 
appearance 
Characteristics Treatment 
option 
Phenylketonuria Neonatal Intellectual disability, autism, 
epilepsy 
Special diet 
Purine 
metabolism 
disorders 
From childhood Development delay, autistic 
characteristics, impulsivity, epilepsy
None 
Creatine 
deficiency 
syndromes 
3 months – 2 
years 
Autistic characteristics, 
epilepsy/myoclonic twitches, 
language and developmental delays, 
extrapyramidal symptoms 
Creatine 
substitution 
Cholesterol 
synthesis defects
From childhood Autism, psychomotor retardation Cholesterol 
suppletion 
Urea cycle 
disorders 
Neonatal and 
postnatal 
Hyperactivity, epilepsy, intellectual 
disability, autism 
Special diet 
measures 
Sanfilippo 
syndrome 
Variable, 
depending on 
subtype 
Loss of acquired skills, autism None 
Mitochondrial 
disorders 
Variable, 
depending on 
subtype 
Depending on organ system None 
Table 2. Metabolic disorders and autism (adapted from Zecavati & Spence, 2009 and Manzi 
et al., 2008) 
The main organ involved in creatine deficiency syndromes is the central nervous system. 
Patients show severe neurodevelopmental delay and, from early infancy on, mental 
retardation, epilepsy, disturbances in active and comprehensible speech, autism and self-
injurious behaviour become prominent (Salomons et al., 2003; Béard and Braissant, 2010). In 
patients with GAMT or AGAT deficiency, early oral creatine substitution treatment might 
effectively prevent neurological sequelae. In those with a defect in the creatine transporter 
gene SLC6A8, however, suppletion with L-arginine is not effective at all (Nasrallah et al., 
2009). 
Although metabolic syndromes should always be involved in the differential diagnosis of 
autism spectrum disorder, systematic screening of such patients is only mandatory in case 
of a suggestive actual symptomatology and/or developmental history. An example is the 
Sanfilippo B syndrome, a mucopolysaccharidosis caused by a mutation in the NAGLU gene, 
which leads to an accumulation of heparan sulfate with, as a consequence, damage to the 
central nervous system and various organ systems. This diagnosis was recently determined 
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for an older, mild intellectually disabled patient who was referred for behavior problems 
with a history of limited verbal and emotional communication, stereotypies, impulsivity, 
and anxieties (Verhoeven et al., 2010). 
5. Closing remarks 
The majority of patients with autism present with a mild to severe intellectual disability. In a 
substantial number of cases, moreover, the autistic disorder appears to be part of a genetic 
disorder. It is quite remarkable therefore, that only one genetic disorder from the array of 
genetic disorders associated with autism, is included in the DSM-category of autistic 
disorders, namely the neurodegenerative Rett syndrome. It should, however, be 
emphasized that the identification of autistic behaviours and the diagnosis of an autism 
spectrum disorder is extremely difficult in patients with severe intellectual disability in the 
context of a genetic syndrome (Moss & Howlin, 2009). It is also evident that in case of 
exceptionally high intelligence, Asperger’s disorder or atypical autism are usually the 
autistic disorders involved. For this specific group of patients, however, no information on 
genetics is available as yet. These patients are often subsumed under the general DSM 
category ’Pervasive Developmental Disorder,Not Otherwise Specified’. 
Apart from the changes of diagnostic concepts over the past decades, research on the genetic 
underpinnings of autism and related disorders confronts three major complexities. First, 
there is the large degree of genetic heterogeneity, which means that different genes can 
contribute in a varying way to the emergence of a disorder. A second difficulty is the 
polygenetic inheritance; that is, the simultaneous presence of multiple genetically-
determined vulnerabilities that may be responsible for the development of a particular 
syndrome. A third problem lies in the well-known interaction between environmental and 
genetic factors during development from early conception on (Volkmar et al., 2009).  
All mutations that are causative for the aforementioned disorders concern genes involved in 
the early development of the central nervous system. The search for susceptibility genes has 
made it clear that disturbed synaptic transmission in, for example, the neuroligin network is 
involved in the pathophysiology of a certain, albeit small, percentage of cases with autism. 
This kind of knowledge might be relevant for the development of putative future 
pharmacological treatment strategies for a subgroup of patients with autism. In this context, 
the earlier mentioned significance of the neuropeptide OXT could also be noteworthy. 
The results from a large number of studies during the past decades lead to several 
conclusions. It is clear that autism, both phenotypically and genotypically, is a very 
heterogeneous disorder and that the quest for the grail of a single-high-impact gene will 
never succeed. In general, mutations or common variants in genes are thought to be 
involved in the neuronal domains, synaptic interaction, neurotransmission, and cell 
migration and growth (Freitag et al., 2010). Attention should therefore be shifted to large-
scale screening for de novo mutations and CNVs that can influence the functioning of a gene 
(Sebat et al., 2007; Vissers et al., 2010).  
Recently, all information available on the vulnerability genes and CNVs associated with 
autism has become available via the Autism Genetic Database (AGD), that can be freely 
accessed at http://wren.bcf.ku.edu (Matuszek & Talebizadeh, 2009). In addition, modern 
fMRI techniques may be of use to map neuronal endophenotypes that are critical for further 
genetic studies of autism (Losh et al., 2008; Piggot et al., 2009).  
For daily clinical practice, facial dysmorphisms in patients with autism in addition to 
intellectual disabilities, constitute the initial indication for modern genetic investigation. 
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Epilepsy at young age and gradual deterioration of previously acquired skills warrant 
further search for a metabolic disorder. Future scientific studies may reveal to which extent 
sets of genes are involved in the pathophysiology of autism and autism related disorders 
per se, but also of neuropsychiatric disorders in general (Lichtenstein et a., 2010). In all cases 
it is clear that detailed information about developmental history, neuropsychiatric/ 
neuropsychological profile as well as an elaborative inventory of family characteristics is 
mandatory for appropriate genetic search. This holds true for both the individual patient 
and for a group of well defined patients. 
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